Kymera Therapeutics (KYMR) Current Assets (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Current Assets of $677.4 million for Q1 2026, up 35.23% year-over-year from $501.0 million in Q1 2025, and down 22.24% quarter-over-quarter from $871.2 million in Q4 2025.
Kymera Therapeutics (KYMR) Current Assets (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Current Assets for 8 consecutive years, with $677.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 35.23% year-over-year to $677.4 million; the TTM figure through Mar 2026 stood at $677.4 million (up 35.23% YoY), while the FY2025 annual figure was $871.2 million, up 70.74% from the prior year.
- Current Assets fell to $677.4 million in Q1 2026 per KYMR's latest filing, from $871.2 million in the prior quarter.
- Across five years, Current Assets topped out at $871.2 million in Q4 2025 and bottomed at $375.7 million in Q3 2023.
- Historically, Current Assets has averaged $516.1 million across 5 years, with a median of $501.0 million in 2025.
- Annual changes were most pronounced in 2023 — Current Assets declined 23.95% — and 2025, when it jumped 70.74%.
- Kymera Therapeutics' Current Assets stood at $419.4 million in 2022, then retreated by 3.36% to $405.3 million in 2023, then grew by 25.89% to $510.3 million in 2024, then surged by 70.74% to $871.2 million in 2025, then decreased by 22.24% to $677.4 million in 2026.
- Business Quant data shows KYMR's Current Assets at $677.4 million in Q1 2026, $871.2 million in Q4 2025, and $528.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 737.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 737.27 Mn |
| Mar 31, 2026 | 677.43 Mn |
| Dec 31, 2025 | 871.21 Mn |
| Sep 30, 2025 | 528.30 Mn |
| Jun 30, 2025 | 728.33 Mn |
| Mar 31, 2025 | 500.95 Mn |
| Dec 31, 2024 | 510.27 Mn |
| Sep 30, 2024 | 568.72 Mn |
| Jun 30, 2024 | 525.41 Mn |
| Mar 31, 2024 | 537.25 Mn |
| Dec 31, 2023 | 405.32 Mn |
| Sep 30, 2023 | 375.69 Mn |
| Jun 30, 2023 | 385.40 Mn |
| Mar 31, 2023 | 411.55 Mn |
| Dec 31, 2022 | 419.42 Mn |
| Sep 30, 2022 | 494.02 Mn |
| Jun 30, 2022 | 402.77 Mn |
| Mar 31, 2022 | 431.38 Mn |
| Dec 31, 2021 | 451.27 Mn |
| Sep 30, 2021 | 543.73 Mn |